aTyr Pharma Updates Timeline for Phase 3 Study of Pulmonary Sarcoidosis Drug

The biotechnology company announced a revised schedule for receiving regulatory feedback on its planned clinical trial for efzofitimod, a treatment targeting pulmonary sarcoidosis.

1 Sept, 20:36 — 1 Sept, 20:36

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual21h ago

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - taiwannews.com.tw

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis taiwannews.com.tw

Read full article →

aTyr Pharma Updates Timeline for Phase 3 Study of Pulmonary Sarcoidosis Drug

Sources

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - taiwannews.com.tw

Related Stories

Tiger Woods Pleads Guilty to Reckless Driving, Banned for 5 Years

Netherlands Transfers 86 Tons of Gold Reserves to London Over Geopolitical Fears

Rubio Defends CIA Director’s Routine Moscow Visit as Intelligence Liaison Effort

Macron Opens UK Visit by Viewing Bayeux Tapestry With King Charles III